 | • レポートコード：GIR-105X12183 • 出版社/出版日： / 2021年5月 • レポート形態：英文、PDF、98ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：Pharma & Healthcare |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、多発性骨髄腫治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。多発性骨髄腫治療薬の種類別市場規模（化学療法、コルチコステロイド、免疫調節剤、モノクローナル抗体、ヒストンデアセチラーゼ（HDAC）阻害剤、プロテアソーム阻害剤、その他）、用途別市場規模（男性、女性）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・多発性骨髄腫治療薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Amgen、Johnson & Johnson、Celgene、Takeda Pharmaceutical、Novartis、Daiichi Sankyo、Merck、AB Science、Teva、PharmaMar ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：化学療法、コルチコステロイド、免疫調節剤、モノクローナル抗体、ヒストンデアセチラーゼ（HDAC）阻害剤、プロテアソーム阻害剤、その他 ・用途別分析2016年-2026年：男性、女性 ・多発性骨髄腫治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・多発性骨髄腫治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・多発性骨髄腫治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・多発性骨髄腫治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・多発性骨髄腫治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Multiple Myeloma Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Multiple Myeloma Drugs size is estimated to be xx million in 2021 from USD xx million in 2020, with a change of XX% between 2020 and 2021. The global Multiple Myeloma Drugs market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Multiple Myeloma Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Chemotherapy
Corticosteroids
Immunomodulators
Monoclonal Antibodies
Histone Deacetylase (HDAC) Inhibitors
Proteasome Inhibitors
Others
Market segment by Application can be divided into
Men
Women
The key market players for global Multiple Myeloma Drugs market are listed below:
Amgen
Johnson & Johnson
Celgene
Takeda Pharmaceutical
Novartis
Daiichi Sankyo
Merck
AB Science
Teva
PharmaMar
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Multiple Myeloma Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Multiple Myeloma Drugs, with price, sales, revenue and global market share of Multiple Myeloma Drugs from 2019 to 2021.
Chapter 3, the Multiple Myeloma Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Multiple Myeloma Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2016 to 2026.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2016 to 2026.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Multiple Myeloma Drugs market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Multiple Myeloma Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Multiple Myeloma Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Multiple Myeloma Drugs Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Chemotherapy
1.2.3 Corticosteroids
1.2.4 Immunomodulators
1.2.5 Monoclonal Antibodies
1.2.6 Histone Deacetylase (HDAC) Inhibitors
1.2.7 Proteasome Inhibitors
1.2.8 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Multiple Myeloma Drugs Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Men
1.3.3 Women
1.4 Global Multiple Myeloma Drugs Market Size & Forecast
1.4.1 Global Multiple Myeloma Drugs Sales in Value (2016-2026))
1.4.2 Global Multiple Myeloma Drugs Sales in Volume (2016-2026)
1.4.3 Global Multiple Myeloma Drugs Price by Type (2016-2026) & (USD/Unit)
1.5 Global Multiple Myeloma Drugs Production Capacity Analysis
1.5.1 Global Multiple Myeloma Drugs Total Production Capacity (2016-2026)
1.5.2 Global Multiple Myeloma Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Multiple Myeloma Drugs Market Drivers
1.6.2 Multiple Myeloma Drugs Market Restraints
1.6.3 Multiple Myeloma Drugs Trends Analysis
2 Manufacturers Profiles
2.1 Amgen
2.1.1 Amgen Details
2.1.2 Amgen Major Business
2.1.3 Amgen Multiple Myeloma Drugs Product and Services
2.1.4 Amgen Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 Johnson & Johnson
2.2.1 Johnson & Johnson Details
2.2.2 Johnson & Johnson Major Business
2.2.3 Johnson & Johnson Multiple Myeloma Drugs Product and Services
2.2.4 Johnson & Johnson Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 Celgene
2.3.1 Celgene Details
2.3.2 Celgene Major Business
2.3.3 Celgene Multiple Myeloma Drugs Product and Services
2.3.4 Celgene Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 Takeda Pharmaceutical
2.4.1 Takeda Pharmaceutical Details
2.4.2 Takeda Pharmaceutical Major Business
2.4.3 Takeda Pharmaceutical Multiple Myeloma Drugs Product and Services
2.4.4 Takeda Pharmaceutical Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Novartis
2.5.1 Novartis Details
2.5.2 Novartis Major Business
2.5.3 Novartis Multiple Myeloma Drugs Product and Services
2.5.4 Novartis Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 Daiichi Sankyo
2.6.1 Daiichi Sankyo Details
2.6.2 Daiichi Sankyo Major Business
2.6.3 Daiichi Sankyo Multiple Myeloma Drugs Product and Services
2.6.4 Daiichi Sankyo Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.7 Merck
2.7.1 Merck Details
2.7.2 Merck Major Business
2.7.3 Merck Multiple Myeloma Drugs Product and Services
2.7.4 Merck Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.8 AB Science
2.8.1 AB Science Details
2.8.2 AB Science Major Business
2.8.3 AB Science Multiple Myeloma Drugs Product and Services
2.8.4 AB Science Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.9 Teva
2.9.1 Teva Details
2.9.2 Teva Major Business
2.9.3 Teva Multiple Myeloma Drugs Product and Services
2.9.4 Teva Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.10 PharmaMar
2.10.1 PharmaMar Details
2.10.2 PharmaMar Major Business
2.10.3 PharmaMar Multiple Myeloma Drugs Product and Services
2.10.4 PharmaMar Multiple Myeloma Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Multiple Myeloma Drugs Sales by Manufacturer
3.1 Global Multiple Myeloma Drugs Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Multiple Myeloma Drugs Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Multiple Myeloma Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Multiple Myeloma Drugs Manufacturer Market Share
3.4.2 Top 6 Multiple Myeloma Drugs Manufacturer Market Share
3.5 Global Multiple Myeloma Drugs Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Multiple Myeloma Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Multiple Myeloma Drugs Market Size by Region
4.1.1 Global Multiple Myeloma Drugs Sales in Volume by Region (2016-2026)
4.1.2 Global Multiple Myeloma Drugs Revenue by Region (2016-2026)
4.2 North America Multiple Myeloma Drugs Revenue (2016-2026)
4.3 Europe Multiple Myeloma Drugs Revenue (2016-2026)
4.4 Asia-Pacific Multiple Myeloma Drugs Revenue (2016-2026)
4.5 South America Multiple Myeloma Drugs Revenue (2016-2026)
4.6 Middle East and Africa Multiple Myeloma Drugs Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Multiple Myeloma Drugs Sales in Volume by Type (2016-2026)
5.2 Global Multiple Myeloma Drugs Revenue by Type (2016-2026)
5.3 Global Multiple Myeloma Drugs Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Multiple Myeloma Drugs Sales in Volume by Application (2016-2026)
6.2 Global Multiple Myeloma Drugs Revenue by Application (2016-2026)
6.3 Global Multiple Myeloma Drugs Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Multiple Myeloma Drugs Sales by Type (2016-2026)
7.2 North America Multiple Myeloma Drugs Sales by Application (2016-2026)
7.3 North America Multiple Myeloma Drugs Market Size by Country
7.3.1 North America Multiple Myeloma Drugs Sales in Volume by Country (2016-2026)
7.3.2 North America Multiple Myeloma Drugs Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Multiple Myeloma Drugs Sales by Type (2016-2026)
8.2 Europe Multiple Myeloma Drugs Sales by Application (2016-2026)
8.3 Europe Multiple Myeloma Drugs Market Size by Country
8.3.1 Europe Multiple Myeloma Drugs Sales in Volume by Country (2016-2026)
8.3.2 Europe Multiple Myeloma Drugs Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Multiple Myeloma Drugs Sales by Type (2016-2026)
9.2 Asia-Pacific Multiple Myeloma Drugs Sales by Application (2016-2026)
9.3 Asia-Pacific Multiple Myeloma Drugs Market Size by Region
9.3.1 Asia-Pacific Multiple Myeloma Drugs Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Multiple Myeloma Drugs Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Multiple Myeloma Drugs Sales by Type (2016-2026)
10.2 South America Multiple Myeloma Drugs Sales by Application (2016-2026)
10.3 South America Multiple Myeloma Drugs Market Size by Country
10.3.1 South America Multiple Myeloma Drugs Sales in Volume by Country (2016-2026)
10.3.2 South America Multiple Myeloma Drugs Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Multiple Myeloma Drugs Sales by Type (2016-2026)
11.2 Middle East & Africa Multiple Myeloma Drugs Sales by Application (2016-2026)
11.3 Middle East & Africa Multiple Myeloma Drugs Market Size by Country
11.3.1 Middle East & Africa Multiple Myeloma Drugs Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Multiple Myeloma Drugs Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Multiple Myeloma Drugs Typical Distributors
12.3 Multiple Myeloma Drugs Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Multiple Myeloma Drugs Revenue by Type, (USD Million), 2021-2026
Table 2. Global Multiple Myeloma Drugs Revenue by Application, (USD Million), 2021-2026
Table 3. Amgen Basic Information, Manufacturing Base and Competitors
Table 4. Amgen Major Business
Table 5. Amgen Multiple Myeloma Drugs Product and Services
Table 6. Amgen Multiple Myeloma Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 8. Johnson & Johnson Major Business
Table 9. Johnson & Johnson Multiple Myeloma Drugs Product and Services
Table 10. Johnson & Johnson Multiple Myeloma Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Celgene Basic Information, Manufacturing Base and Competitors
Table 12. Celgene Major Business
Table 13. Celgene Multiple Myeloma Drugs Product and Services
Table 14. Celgene Multiple Myeloma Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Takeda Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 16. Takeda Pharmaceutical Major Business
Table 17. Takeda Pharmaceutical Multiple Myeloma Drugs Product and Services
Table 18. Takeda Pharmaceutical Multiple Myeloma Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Novartis Basic Information, Manufacturing Base and Competitors
Table 20. Novartis Major Business
Table 21. Novartis Multiple Myeloma Drugs Product and Services
Table 22. Novartis Multiple Myeloma Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Daiichi Sankyo Basic Information, Manufacturing Base and Competitors
Table 24. Daiichi Sankyo Major Business
Table 25. Daiichi Sankyo Multiple Myeloma Drugs Product and Services
Table 26. Daiichi Sankyo Multiple Myeloma Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Merck Basic Information, Manufacturing Base and Competitors
Table 28. Merck Major Business
Table 29. Merck Multiple Myeloma Drugs Product and Services
Table 30. Merck Multiple Myeloma Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. AB Science Basic Information, Manufacturing Base and Competitors
Table 32. AB Science Major Business
Table 33. AB Science Multiple Myeloma Drugs Product and Services
Table 34. AB Science Multiple Myeloma Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Teva Basic Information, Manufacturing Base and Competitors
Table 36. Teva Major Business
Table 37. Teva Multiple Myeloma Drugs Product and Services
Table 38. Teva Multiple Myeloma Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 39. PharmaMar Basic Information, Manufacturing Base and Competitors
Table 40. PharmaMar Major Business
Table 41. PharmaMar Multiple Myeloma Drugs Product and Services
Table 42. PharmaMar Multiple Myeloma Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 43. Global Multiple Myeloma Drugs Sales by Manufacturer (2019-2021e) & (K Units)
Table 44. Global Multiple Myeloma Drugs Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 45. Market Position of Manufacturers in Multiple Myeloma Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 46. Global Multiple Myeloma Drugs Production Capacity by Company, (K Units): 2020 VS 2021
Table 47. Head Office and Multiple Myeloma Drugs Production Site of Key Manufacturer
Table 48. Multiple Myeloma Drugs New Entrant and Capacity Expansion Plans
Table 49. Multiple Myeloma Drugs Mergers & Acquisitions in the Past Five Years
Table 50. Global Multiple Myeloma Drugs Sales by Region (2016-2021e) & (K Units)
Table 51. Global Multiple Myeloma Drugs Sales by Region (2021-2026) & (K Units)
Table 52. Global Multiple Myeloma Drugs Revenue by Region (2016-2021e) & (USD Million)
Table 53. Global Multiple Myeloma Drugs Revenue by Region (2021-2026) & (USD Million)
Table 54. Global Multiple Myeloma Drugs Sales by Type (2016-2021e) & (K Units)
Table 55. Global Multiple Myeloma Drugs Sales by Type (2021-2026) & (K Units)
Table 56. Global Multiple Myeloma Drugs Revenue by Type (2016-2021e) & (USD Million)
Table 57. Global Multiple Myeloma Drugs Revenue by Type (2021-2026) & (USD Million)
Table 58. Global Multiple Myeloma Drugs Price by Type (2016-2021e) & (USD/Unit)
Table 59. Global Multiple Myeloma Drugs Price by Type (2021-2026) & (USD/Unit)
Table 60. Global Multiple Myeloma Drugs Sales by Application (2016-2021e) & (K Units)
Table 61. Global Multiple Myeloma Drugs Sales by Application (2021-2026) & (K Units)
Table 62. Global Multiple Myeloma Drugs Revenue by Application (2016-2021e) & (USD Million)
Table 63. Global Multiple Myeloma Drugs Revenue by Application (2021-2026) & (USD Million)
Table 64. Global Multiple Myeloma Drugs Price by Application (2016-2021e) & (USD/Unit)
Table 65. Global Multiple Myeloma Drugs Price by Application (2021-2026) & (USD/Unit)
Table 66. North America Multiple Myeloma Drugs Sales by Country (2016-2021e) & (K Units)
Table 67. North America Multiple Myeloma Drugs Sales by Country (2021-2026) & (K Units)
Table 68. North America Multiple Myeloma Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 69. North America Multiple Myeloma Drugs Revenue by Country (2021-2026) & (USD Million)
Table 70. North America Multiple Myeloma Drugs Sales by Type (2016-2021e) & (K Units)
Table 71. North America Multiple Myeloma Drugs Sales by Type (2021-2026) & (K Units)
Table 72. North America Multiple Myeloma Drugs Sales by Application (2016-2021e) & (K Units)
Table 73. North America Multiple Myeloma Drugs Sales by Application (2021-2026) & (K Units)
Table 74. Europe Multiple Myeloma Drugs Sales by Country (2016-2021e) & (K Units)
Table 75. Europe Multiple Myeloma Drugs Sales by Country (2021-2026) & (K Units)
Table 76. Europe Multiple Myeloma Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 77. Europe Multiple Myeloma Drugs Revenue by Country (2021-2026) & (USD Million)
Table 78. Europe Multiple Myeloma Drugs Sales by Type (2016-2021e) & (K Units)
Table 79. Europe Multiple Myeloma Drugs Sales by Type (2021-2026) & (K Units)
Table 80. Europe Multiple Myeloma Drugs Sales by Application (2016-2021e) & (K Units)
Table 81. Europe Multiple Myeloma Drugs Sales by Application (2021-2026) & (K Units)
Table 82. Asia-Pacific Multiple Myeloma Drugs Sales by Region (2016-2021e) & (K Units)
Table 83. Asia-Pacific Multiple Myeloma Drugs Sales by Region (2021-2026) & (K Units)
Table 84. Asia-Pacific Multiple Myeloma Drugs Revenue by Region (2016-2021e) & (USD Million)
Table 85. Asia-Pacific Multiple Myeloma Drugs Revenue by Region (2021-2026) & (USD Million)
Table 86. Asia-Pacific Multiple Myeloma Drugs Sales by Type (2016-2021e) & (K Units)
Table 87. Asia-Pacific Multiple Myeloma Drugs Sales by Type (2021-2026) & (K Units)
Table 88. Asia-Pacific Multiple Myeloma Drugs Sales by Application (2016-2021e) & (K Units)
Table 89. Asia-Pacific Multiple Myeloma Drugs Sales by Application (2021-2026) & (K Units)
Table 90. South America Multiple Myeloma Drugs Sales by Country (2016-2021e) & (K Units)
Table 91. South America Multiple Myeloma Drugs Sales by Country (2021-2026) & (K Units)
Table 92. South America Multiple Myeloma Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 93. South America Multiple Myeloma Drugs Revenue by Country (2021-2026) & (USD Million)
Table 94. South America Multiple Myeloma Drugs Sales by Type (2016-2021e) & (K Units)
Table 95. South America Multiple Myeloma Drugs Sales by Type (2021-2026) & (K Units)
Table 96. South America Multiple Myeloma Drugs Sales by Application (2016-2021e) & (K Units)
Table 97. South America Multiple Myeloma Drugs Sales by Application (2021-2026) & (K Units)
Table 98. Middle East & Africa Multiple Myeloma Drugs Sales by Country (2016-2021e) & (K Units)
Table 99. Middle East & Africa Multiple Myeloma Drugs Sales by Country (2021-2026) & (K Units)
Table 100. Middle East & Africa Multiple Myeloma Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 101. Middle East & Africa Multiple Myeloma Drugs Revenue by Country (2021-2026) & (USD Million)
Table 102. Middle East & Africa Multiple Myeloma Drugs Sales by Type (2016-2021e) & (K Units)
Table 103. Middle East & Africa Multiple Myeloma Drugs Sales by Type (2021-2026) & (K Units)
Table 104. Middle East & Africa Multiple Myeloma Drugs Sales by Application (2016-2021e) & (K Units)
Table 105. Middle East & Africa Multiple Myeloma Drugs Sales by Application (2021-2026) & (K Units)
Table 106. Direct Channel Pros & Cons
Table 107. Indirect Channel Pros & Cons
Table 108. Multiple Myeloma Drugs Typical Distributors
Table 109. Multiple Myeloma Drugs Typical Customers
List of Figures
Figure 1. Multiple Myeloma Drugs Picture
Figure 2. Global Multiple Myeloma Drugs Sales Market Share by Type in 2020
Figure 3. Chemotherapy
Figure 4. Corticosteroids
Figure 5. Immunomodulators
Figure 6. Monoclonal Antibodies
Figure 7. Histone Deacetylase (HDAC) Inhibitors
Figure 8. Proteasome Inhibitors
Figure 9. Others
Figure 10. Global Multiple Myeloma Drugs Sales Market Share by Application in 2020
Figure 11. Men
Figure 12. Women
Figure 13. Global Multiple Myeloma Drugs Market Size, (USD Million) & (K Units): 2020 VS 2021 VS 2026
Figure 14. Global Multiple Myeloma Drugs Market Size and Forecast (2016-2026) & (USD Million)
Figure 15. Global Multiple Myeloma Drugs Sales (2016-2026) & (K Units)
Figure 16. Global Multiple Myeloma Drugs Price by Type (2016-2026) & (USD/Unit)
Figure 17. Global Multiple Myeloma Drugs Production Capacity (2016-2026) & (K Units)
Figure 18. Global Multiple Myeloma Drugs Production Capacity by Geographic Region: 2020 VS 2021
Figure 19. Multiple Myeloma Drugs Market Drivers
Figure 20. Multiple Myeloma Drugs Market Restraints
Figure 21. Multiple Myeloma Drugs Market Trends
Figure 22. Global Multiple Myeloma Drugs Sales Market Share by Manufacturer in 2020
Figure 23. Global Multiple Myeloma Drugs Revenue Market Share by Manufacturer in 2020
Figure 24. Multiple Myeloma Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 25. Top 3 Multiple Myeloma Drugs Manufacturer (Revenue) Market Share in 2020
Figure 26. Top 6 Multiple Myeloma Drugs Manufacturer (Revenue) Market Share in 2020
Figure 27. Global Multiple Myeloma Drugs Sales Market Share by Region (2016-2026)
Figure 28. Global Multiple Myeloma Drugs Revenue Market Share by Region (2016-2026)
Figure 29. North America Multiple Myeloma Drugs Revenue (2016-2026) & (USD Million)
Figure 30. Europe Multiple Myeloma Drugs Revenue (2016-2026) & (USD Million)
Figure 31. Asia-Pacific Multiple Myeloma Drugs Revenue (2016-2026) & (USD Million)
Figure 32. South America Multiple Myeloma Drugs Revenue (2016-2026) & (USD Million)
Figure 33. Middle East & Africa Multiple Myeloma Drugs Revenue (2016-2026) & (USD Million)
Figure 34. Global Multiple Myeloma Drugs Sales Market Share by Type (2016-2026)
Figure 35. Global Multiple Myeloma Drugs Revenue Market Share by Type (2016-2026)
Figure 36. Global Multiple Myeloma Drugs Price by Type (2016-2026) & (USD/Unit)
Figure 37. Global Multiple Myeloma Drugs Sales Market Share by Application (2016-2026)
Figure 38. Global Multiple Myeloma Drugs Revenue Market Share by Application (2016-2026)
Figure 39. Global Multiple Myeloma Drugs Price by Application (2016-2026) & (USD/Unit)
Figure 40. North America Multiple Myeloma Drugs Sales Market Share by Type (2016-2026)
Figure 41. North America Multiple Myeloma Drugs Sales Market Share by Application (2016-2026)
Figure 42. North America Multiple Myeloma Drugs Sales Market Share by Country (2016-2026)
Figure 43. North America Multiple Myeloma Drugs Revenue Market Share by Country (2016-2026)
Figure 44. United States Multiple Myeloma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Canada Multiple Myeloma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Mexico Multiple Myeloma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Europe Multiple Myeloma Drugs Sales Market Share by Type (2016-2026)
Figure 48. Europe Multiple Myeloma Drugs Sales Market Share by Application (2016-2026)
Figure 49. Europe Multiple Myeloma Drugs Sales Market Share by Country (2016-2026)
Figure 50. Europe Multiple Myeloma Drugs Revenue Market Share by Country (2016-2026)
Figure 51. Germany Multiple Myeloma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. France Multiple Myeloma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. United Kingdom Multiple Myeloma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Russia Multiple Myeloma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Italy Multiple Myeloma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Asia-Pacific Multiple Myeloma Drugs Sales Market Share by Region (2016-2026)
Figure 57. Asia-Pacific Multiple Myeloma Drugs Sales Market Share by Application (2016-2026)
Figure 58. Asia-Pacific Multiple Myeloma Drugs Sales Market Share by Region (2016-2026)
Figure 59. Asia-Pacific Multiple Myeloma Drugs Revenue Market Share by Region (2016-2026)
Figure 60. China Multiple Myeloma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Japan Multiple Myeloma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Korea Multiple Myeloma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. India Multiple Myeloma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Southeast Asia Multiple Myeloma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Australia Multiple Myeloma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. South America Multiple Myeloma Drugs Sales Market Share by Type (2016-2026)
Figure 67. South America Multiple Myeloma Drugs Sales Market Share by Application (2016-2026)
Figure 68. South America Multiple Myeloma Drugs Sales Market Share by Country (2016-2026)
Figure 69. South America Multiple Myeloma Drugs Revenue Market Share by Country (2016-2026)
Figure 70. Brazil Multiple Myeloma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Argentina Multiple Myeloma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Middle East & Africa Multiple Myeloma Drugs Sales Market Share by Type (2016-2026)
Figure 73. Middle East & Africa Multiple Myeloma Drugs Sales Market Share by Application (2016-2026)
Figure 74. Middle East & Africa Multiple Myeloma Drugs Sales Market Share by Country (2016-2026)
Figure 75. Middle East & Africa Multiple Myeloma Drugs Revenue Market Share by Country (2016-2026)
Figure 76. Turkey Multiple Myeloma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Egypt Multiple Myeloma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Saudi Arabia Multiple Myeloma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. South Africa Multiple Myeloma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
Figure 81. Methodology
Figure 82. Research Process and Data Source
全身性エリテマトーデス（SLE）薬の世界市場予測 2023年：メーカー別、地域別、種類・用途別 SLE is the most common form of lupus and is also called lupus. It is a chronic, autoimmune disease with signs and symptoms that can last for six months or for many years. It can affect any part of the body, such as the skin, joints, and organs (LFA, 2012). SLE occurs when the immune system produces …- 多発性硬化症治療薬の世界市場2018-2025 Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (central nervous system). In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between your brain and the rest of your body. Eventually, the d…
- タイサブリ薬の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Tysabri (natalizumab) is a monoclonal antibody used in to treat relapsing forms of multiple sclerosis. Tysabri is also used to treat moderate to severe Crohn's disease in adults. Tysabri is usually given after other Crohn's disease medications have been tried without successful treatment of this con…
- 腎臓がんの薬の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Kidney cancer, also known as renal cancer, is a type of cancer that starts in the cells in the kidney. The two most common types of kidney cancer are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC) of the renal pelvis. These names reflect the type of cell from which the cancer devel…
- エピジェネティック薬・診断テクノロジ－の世界市場2018-2025 The drugs and technologies that treat the reletive diseasesRising incidence of gene expression changes due to chemical modifications in DNA or chromatin is the major factor driving the growth of epigenetics drugs and diagnostic technologies market Increasing demand for epigenetics drugs and diagnost…